Silexion Therapeutics (NASDAQ:SLXN) Trading Down 2.3% – Here’s Why

Silexion Therapeutics Corp (NASDAQ:SLXN)’s stock price fell 2.3% during mid-day trading on Friday . The stock traded as low as $0.5801 and last traded at $0.5983. 167,411 shares were traded during mid-day trading, an increase of 60% from the average session volume of 104,441 shares. The stock had previously closed at $0.6121.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Wednesday, March 18th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

Silexion Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.60, a quick ratio of 2.41 and a current ratio of 2.41. The business has a 50-day moving average price of $1.30 and a 200 day moving average price of $2.08. The stock has a market capitalization of $1.99 million, a P/E ratio of -0.05 and a beta of -0.28.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.